This is why many people view MIC injections as a dual purpose option for energy and weight management
Strength training on Wegovy or other semaglutide formulations does not need to be extreme
Findings: RCTSURMOUNT-2 trial - Tirzepatide vs Placebo for Weight Loss in Diabetes, Lancet (2023) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=938 | length = 72 weeks) in overweight diabetics (mean BMI 36 | mean A1C 8.02%) Treatment: Tirzepatide 10 mg once weekly vs Tirzepatide 15 mg once weekly vs Placebo Primary outcome: Coprimary endpoints were the percent change in body weight from baseline and body weight reduction of 5% or higher Results: Primary outcome (% reduction in weight): Tirzepatide 10 mg - 12.8%, Tirzepatide 15 mg - 14.7%, Placebo - 3.2% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached
Vitamin injections offer a quick and effective way to address common health concerns
Dr Kim Boyd, chief medical officer at the company said: "GLP-1 medications are powerful tools, but they're not a standalone solution." She added: "They work across the body, including the brain, to reduce hunger signals and food noise - something that can be especially helpful during the festive season." Boyd said the programme helps translate the biological effects of GLP-1 medications into sustainable behaviour change, with science-backed support that spans dose and side-effect tracking, nutrition and movement guidance to help preserve muscle, and a community designed specifically for people on a GLP-1 journey
